TI
NBIX icon

tru Independence’s Neurocrine Biosciences NBIX Stock Holding History

tru Independence’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18
Closed -$2 – 658
2020
Q2 		$2 Hold
18
– – ﹤0.01% 806
2020
Q1 		$2 Hold
18
– – ﹤0.01% 636
2019
Q4 		$2K Buy
+18
New +$1.89K ﹤0.01% 813

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

tru Independence's NBIX Position: Q3 2020 in Review

tru Independence sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 18 shares — an estimated $2 sold.

tru Independence first reported a position in NBIX in Q4 2019 and held it in 3 quarters. The position peaked at $2K in Q4 2019. 418 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

  • tru Independence reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 18 Neurocrine Biosciences shares in Q3 2020, an estimated $2.
  • tru Independence first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 3 quarters.
  • tru Independence's Neurocrine Biosciences position peaked at $2K in Q4 2019.
  • 418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.